Who Exports Dasatinib from India — 110 Suppliers Behind a $16.4M Market

Hyderabad, often referred to as the "Bulk Drug Capital of India," is a major hub for the production of active pharmaceutical ingredients (APIs). The city hosts over 800 pharmaceutical companies, including industry leaders such as Dr. Reddy's Laboratories and Aurobindo Pharma. The presence of Genome Valley, India's first biotech cluster, along with advanced research institutions like the National Institute of Pharmaceutical Education and Research (NIPER), provides a robust infrastructure for drug development and manufacturing. This ecosystem makes Hyderabad a critical center for the production of APIs like Dasatinib.

The Ahmedabad-Vadodara corridor in Gujarat is renowned for its focus on pharmaceutical formulations. Gujarat contributes nearly 28% of India's pharmaceutical production and is home to major companies such as Zydus Cadila, Intas Pharmaceuticals, and Torrent Pharmaceuticals. The region's well-developed infrastructure, including ports and transportation networks, facilitates efficient manufacturing and export of finished pharmaceutical products, including Dasatinib tablets.

The Mumbai-Thane-Raigad belt serves as a significant export gateway for India's pharmaceutical industry. Mumbai, being the financial capital, hosts numerous pharmaceutical companies with a strong focus on international markets. The region's proximity to major ports enhances its capacity for exporting pharmaceutical products, including Dasatinib, to various countries. Companies like Lupin Limited, headquartered in Mumbai, have leveraged this strategic location to launch products such as Dasatinib tablets in the United States.

Baddi, located in Himachal Pradesh, is recognized as Asia's largest pharmaceutical hub by volume. The region offers tax incentives and a favorable business environment, attracting numerous pharmaceutical manufacturers. Baddi houses over 1,000 pharmaceutical manufacturing units, contributing significantly to India's pharmaceutical output. The presence of companies like Cipla and Dr. Reddy's Laboratories underscores its importance in the pharmaceutical landscape.

• Diversify Supplier Base: Engage with multiple suppliers across different clusters to mitigate risks associated with regional disruptions.

• Evaluate Supplier Capabilities: Assess the manufacturing capabilities and regulatory compliance of suppliers, especially those in Hyderabad for APIs and Ahmedabad-Vadodara for formulations.

• Leverage Export Hubs: Utilize the Mumbai-Thane-Raigad region's export infrastructure for efficient international distribution of Dasatinib products.

• Consider Cost Advantages: Explore sourcing from Baddi-Nalagarh to benefit from tax incentives and cost-effective manufacturing options.

By strategically engaging with these pharmaceutical clusters, TransData Nexus can optimize its supply chain for Dasatinib, ensuring a robust and efficient procurement process.